HRT Financial
IBO

HRT Financial’s Impact BioMedical IBO Stock Holding History

HRT Financial’s Portfolio IBO Stock Details IBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,072
Closed -$6K – 4954
2025
Q4 		$6K Buy
+1,072
New +$7.16K ﹤0.01% 3064
2025
Q3 		– Sell
-818
Closed -$6K – 3857
2025
Q2 		$6K Sell
818
-4,583
-85% -$32.4K ﹤0.01% 2481
2025
Q1 		$59K Buy
+5,401
New +$118K ﹤0.01% 2225
2024
Q4 		– Sell
-991
Closed -$25K – 3425
2024
Q3 		$25K Buy
+991
New +$29.6K ﹤0.01% 2174

Other funds holding IBO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Global Advisers
Vanguard Global Advisers Malvern, Pennsylvania $215B AUM
Mason & Associates (California)
Mason & Associates (California) Los Angeles, California $619M AUM 29.44% 1-Year Est. Return

HRT Financial's IBO Position: Q1 2026 in Review

HRT Financial sold out of Impact BioMedical (IBO) in Q1 2026, closing a stake of 1,072 shares — an estimated $6K sold.

HRT Financial first reported a position in IBO in Q3 2024 and held it in 4 quarters. The position peaked at $59K in Q1 2025. 20 funds tracked by Wall St. Rank hold IBO as of Q1 2026.

  • HRT Financial reported no remaining Impact BioMedical position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 1,072 Impact BioMedical shares in Q1 2026, an estimated $6K.
  • HRT Financial first reported a position in Impact BioMedical in Q3 2024 and held it in 4 quarters.
  • HRT Financial's Impact BioMedical position peaked at $59K in Q1 2025.
  • 20 funds tracked by Wall St. Rank held Impact BioMedical as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.